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Cefpirome is a fourth-generation cephalosporin active against a broad spectrum of gram-negative and gram-positive bacterial 
infections. The present work describe the development and validation of a simple, sensitive and specific agar diffusion bioassay 
applying cylinder-plate method for quantification of cefpirome in raw material and powder for injectable preparation. The 
validation method yielded good results and included linearity, precision, accuracy and specificity. The assay is based on the 
inhibitory effect of cefpirome upon the strain of Kocuria rizophila ATCC 9341 as the test microorganism. The result of assay 
were treated statistically by ANOVA and the response graphs for standard and sample solutions were linear (r = 0.9948) in the 
range of 0.3 – 1.2 µg mL-1, precise (intra-assay: RSD = 0.11; inter-assay: RSD = 0.18) and accurate (mean recovery value = 
99.41%). A preliminary stability study of cefpirome showed that the microbiological assay is specific for the determination 
cefpirome in the presence of its degradation products. The proposed microbiological method allows the quantitation of cefpirome 
in pharmaceutical dosage form and raw material and can be used for the drug analysis in routine quality control. 
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Introduction 
 
Cephalosporins are referred to as the β-
lactam antibiotics, which are among the oldest and 
most frequently prescribed of naturally occurring 
antimicrobial agents. These antibiotics have 
assumed a prominent role in modern antimicrobial 
therapy due to enhanced intrinsic microbiological 
activities and favourable safety profile. 
Traditionally, the cephalosporins are divided into 
first-, second-, third- and fourth-generation agents 
[1,2]. 
Cefpirome, [6R-[6α,7β(Z)]]-1-[[(2-Amino-
4-thiazolyl)(methoxyimino)acetyl] amino]-2-
carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-
em-3-yl]methyl]-6,7-dihydro-5H-
cyclopenta[b]pyrindinium inner salt [3] (Fig. 1), is 
an injectable broad-spectrum aminothiazolyl 
cephalosporin, produced as sulfate salt. Both in 
vitro and in vivo, cefpirome has shown activity 
against a broad spectrum of gram-negative and 
gram-positive organisms, including staphicococci, 
enterococci, Citrobacter species, Enterobacter 
species, and Pseudomonas aeruginosa [2,4-6]. 
The increased spectrum of activity, together with 
high stability against -lactamases and rapid 
transmembrane transport, distinguishes cefpirome 
as an example of a fourth-generation 
cephalosporin and its principal use is in treatment 
for patients’ septic shock or several sepsis [2,4-9]. 
Methods have been reported for the determination 
of cefpirome biological fluids [2,6-12] and 
pharmaceutical dosage forms [13-15]. Until now, 
there isn’t any report for the determination of 
cefpirome in raw material and pharmaceutical 
preparation by biossay. The aim of this study was 
to develop and validate a microbiological assay of 
cepfirome in raw material and injectable.  
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Figure 1. Chemical structure of cefpirome 
 
Material and methods 
 
Chemicals 
The cefpirome standard (assigned with 
content of cefpirome 823 mg/g, batch n°. C 
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150.05 (SS)) was kindly supplied by Aventis 
Pharma (Frankfurt, Germany), pharmaceuticals 
dosage form (Cefrom
®
 - injectable) containing 
cefpirome was obtained commercially from 
Aventis Pharma (São Paulo, Brazil) and it was 
claimed to contain 1 g (as anhydrous base). All 
reagents used were of analytical reagent grade and 
were purchased from Fluka, Merck and Oxoid. 
 
Microorganinsm and inoculum 
The cultures of Kocuria rizophila ATCC 
9341 were cultivated on Grove-Randall No. 1 agar 
[16] at freezing and subcultured to another Grove 
Randall No. 1 agar 24h before the assay and were 
incubated at 35  2 °C. Using sodium chloride 
0.9% sterile solution, the bacteria was suspended 
in order to obtained a dilution culture suspension 
of 25  2% turbidity (transmittance) at 580 nm, 
using a suitable spectrophotometer (Analyser 
model 800, São Paulo, Brazil) and a 10 mm 
diameter test tube of absorption cells against 
sodium chloride 0.9% sterile solution as blank. 
Portions of 2 mL inoculated sodium chloride 0.9% 
were added to 100 mL Grove Randall No. 11 agar 
at 47  2 °C and used as an inoculated layer. 
 
Reference and samples preparation  
The reference and samples solutions were 
prepared using an amount of powder equivalent to 
20 mg of cefpirome that was transferred to 100 
mL volumetric flask with distilled water followed 
by making up to final volume with this solvent 
(200 µg mL
-1
). An aliquot of this solution (3 mL) 
was transferred to the 100 mL volumetric flask 
and made up to final volume with distilled water 
(6 µg mL
-1
). Aliquots of 5 and 10 mL were 
transferred to 100 and 50 mL volumetric flasks 
and the made up to final volume with 0.1 M 
potassium phosphate buffer pH 8.0 to obtain the 
concentrations of 0.3, 0.6 and 1.2 µg mL
-1
. 
 
Cylinder-plate assay  
Microbiological cylinder-plate assay (3x3) 
was used in this study for determination of 
cefpirome. The agar was composed of two 
separate layers. A 20 mL portion of Grove 
Randall No. 11 agar was poured into 100 x 20 mm 
Petri dish as the base layer. After solidification of 
this layer, 5 mL portions of inoculated layer were 
poured onto the base layer [17-19]. Six stainless 
steel cylinders of uniform size (6 x 8 x 10 mm) 
were placed on the surface of inoculated medium. 
Three alternated cylinders were filled with 200 µL 
of reference and sample solutions (three different 
concentrations). After incubation (35  2 °C for 
18h) the zone diameters of the growth inhibition 
were measured (mm) using an electronic digital 
capiler (Starret
®
, model 797B, Itu, Brazil). Twelve 
assays were performed (three assays a day, during 
four consecutive days) using ten plates in each 
assay. 
 
Calculations  
To calculate the activity (potency) of 
cefpirome in raw material and injectable 
preparation the Hewitt [20] equation was used. 
The assay was statistically calculated by the linear 
parallel model and by means of regression 
analysis and verified using analysis of variance 
(ANOVA) [17-20].  
 
Method validation  
The method was validated by determination 
of linearity, precision, accuracy and specificity 
[19,21]. According to the ICH, U.S. and Brazilian 
Pharmacopoeias [17,19,21], the limits of detection 
and quantification are not required for this 
category of assay. 
 
Linearity 
The calibration curve was obtained with 
three doses of the reference standard. The linearity 
was evaluated by linear regression analysis, which 
was calculated by the least-squares regression 
method. Six assays were performed (3 assays a 
day) using ten plates in each assay. 
 
Precision 
 The precision of the assay was determined 
by repeatability (intra-assay) and intermediate 
precision (inter-assay). Repeatability was 
evaluated by assaying three samples at the same 
concentration and during the same day. The 
intermediate precision was verificated by 
comparing the assays on four different days. The 
precision is calculated by relative standard 
deviation (RSD) [19,21,22]. 
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Accuracy  
The accuracy was determined by adding 
known amount of cefpirome reference substance 
to the samples at the beginning of the process. 
Amount of powder equivalent to 20 mg of 
cefpirome (sample) was placed in 100 mL 
volumetric flask and amount of 2 mg of cefpirome 
reference substance were added and made up to 
final volume with distilled water. Aliquot of this 
solution (3 mL) was transferred to the 100 mL 
volumetric flask and made up to final volume with 
distilled water. Aliquots of 5 and 10 mL were 
transferred to 100 and 50 mL volumetric flasks 
and the made up to final volume with 0.1 M 
potassium phosphate buffer pH 8.0 to obtain the 
concentrations of 0.33, 0.66 and 1.32 µg mL
-1 
respectively. The solutions were submitted to the 
cylinder-plate assay described above. The 
percentage recovery of cefpirome reference added 
was calculated using the equation proposed by 
AOAC [22]. 
 
Specificity 
  The specificity was determined by 
measurement in presence of degradation products. 
Commercially obtained samples diluted in 
injectable water at a concentration of 100 mg mL
-1
 
were submitted to accelerated degradation at 40 
°C, in climatic chamber with controlled humidity 
Nova Ética 420 LDC (Nova Ética, São Paulo, 
Brazil), for four days for thermal stress and 6 mg 
mL
-1
 and 600 µg mL
-1
 for photodegradation 
studies using UV light for four hours. In the case 
of the photodegradation studies, the solutions 
were added into quartz cuvettes, which were 
exposed to UV light (254 nm) in a chamber (17 x 
17 x 100 cm) with all mirrored internal surfaces. 
These solutions were then diluted in 0.1 M 
potassium phosphate buffer pH 8.0 to obtain the 
concentrations of 0.3, 0.6 and 1.2 µg mL
-1 
and 
were assayed against freshly prepared solution of 
reference standard and sample at the same 
concentrations. Each sample was analyzed ten 
times. 
 
Analytical solution stability 
The analytical solutions stability was 
determined by comparison of quantitation of 
components in solutions after storage conditions 
(depends on need) to freshly prepared standards. 
In this study, the solutions were kept at room 
temperature for 6 hours and 24 hours when stored 
refrigerated at 5 °C. 
 
Results and Discussion 
The activity of antimicrobial agents may 
be demonstrated under suitable condition by their 
inhibitory effect on microorganisms [17,19]. 
Although the microbiological assay methods 
involve many steps and are time consuming they 
can reveal subtle changes not demonstrable by 
chemical methods [19]. In this work experimental 
3 x 3 design using three dose levels for each 
standard and sample were used following the 
procedure described in Brazilian and European 
Pharmacopoeias [17,18]. The calculation 
procedure normally assumes a direct relationship 
between the observed zone diameter and 
logarithm of applied dose. 
A microbiological assay was proposed as a 
suitable method for the determination of 
cefpirome in raw material and pharmaceutical 
dosage form. The experimental conditions were 
adjusted to accurately determine the performance 
of the assay. A strain of Kocuria rizophila ATCC 
9341 was found to be an appropriate test 
microorganism allowing quantitation of 
cefpirome. Others microorganism were tested 
(Staphylococcus epidermidis ATCC 12228 and 
Staphylococcus aureus ATCC 6538P) but no one 
gave inhibition zone diameters so distinct like 
Kocuria rizophila. 
The assay of antibiotics must be designed 
to permit examination of the validity of the 
mathematical model on which the potency 
equation is based. If a parallel-line model is 
chosen, the two-log dose-response line of the 
preparations to be examined and the standard 
preparation must be linear over the range of doses 
used in the calculation [18,22,23]. For the 
diffusion assay method, the concentration of the 
solutions must be chosen to ensure a linear 
relationship between the logarithm of the dose and 
the response [24] (Fig. 2). The microbiological 
assay described in this work was performed using 
0.1 M potassium phosphate buffer pH 8.0, water 
and 0.1 M potassium phosphate buffer pH 6.0 as 
final solvent at concentration of cefpirome on the 
0.05 to 2.0 g mL-1 range using 1% and 2% of 
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culture suspension of Kocuria rizophila. The best 
result was obtained with 0.1 M potassium 
phosphate buffer pH 8.0 as final solvent, 2% of 
culture suspension of Kocuria rizophila and good 
linearity on the 0.3 – 1.2 g mL-1 range. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Calibration curve for cefpirome, obtained by the 
microbiological cylinder – plate assay. 
 
The calibration curve for cefpirome was 
constructed by plotting log of concentration (g 
mL
-1
) versus zone diameter (mm) (Fig.2). The 
corresponding mean zone diameters for reference 
solutions were 16.40 mm (RDS = 1.88) for the 
lower dose (0.3 g mL-1), 20.01 mm (RDS = 0.90) 
for the medium dose (0.6 g mL-1) and 23.89 mm 
(RDS 1.90) for the higher dose (1.2 g mL-1) 
(Table 1). 
 
Table 1. Experimental values of Inhibition zone diameters for 
reference solutions of cefpirome, using 0.1 M potassium phosphate 
buffer, pH 8.0, by microbiological assay. 
 
Concentration 
(µg mL-1) 
Range of zone size 
Mean diameter zone 
of inhibitiona ± RSD  
(mm ± %) 
0.30 15.90 - 17.58 16.40 ± 1.88 
0.60 19.38 - 21.23 20.01 ± 0.90 
1.20 23.09 - 24.95 23.89 ± 1.90 
a Each value is the mean of 6 assays with 10 plates in each. 
 
According British, European and Brazilian 
Pharmacopoeias [17,18,25], if a parallel-line 
model is chosen, the two log dose-response lines 
of the preparation to be examined and the 
reference preparation must be verifies by validity 
tests for a given probability, usually P = 0.05. The 
assays were validated by means of the analysis of 
variance (ANOVA) as described in these official 
codes. 
There are no deviation from parallelism 
and linearity with results obtained here 
(Fcalculated<Fcritical p = 0.05) as showed in Table 2. 
The representative linear equation for cefpirome 
was y = 12.440x + 10.421 where x is the log dose 
and y the diameter zone and the regression 
coefficient was r = 0.9948 (Fig. 2). 
 
Table 2. Analysis of variance of the data obtained from the 
microbiological method for determination of cefpirome. 
Source of 
variation 
Degrees of 
freedom 
Sum of 
Squares 
Mean 
squares 
F 
Between 2 168.36 84.18 755.10 
Regression 1 168.29 168.29 1509.53a 
Deviation 1 0.07 0.07 0.67 
Within 15 1.67 0.11 ----- 
Total 17 170.03 ----- ----- 
a Significant at P < 0.05 
Each value is the mean of 6 assays with 10 plates in each. 
 
The experimental values obtained for the 
determination of cefpirome in powder for 
injectable are presented in Table 3. The mean 
potency of the sample determined by the 
microbiological assay (721.06 mg per g) was 
inside the acceptance criteria. The 278.94 mg 
remaining was mixture of sulfate, water and 
sodium carbonate. 
 
Table 3. Results of the determination of cefpirome in powder for 
injection by microbiological cylinder – plate assay. 
Sample 
powder for 
injectable 
(mg) 
Experimental 
amounta (mg) 
Potency 
(mg per g) 
RSD (%) 
Intra-
assay 
RSD 
(%) 
Inter-
assay 
30.30 21.85 721.23   
30.10 21.63 718.57 0.18  
30.00 21.60 719.94   
30.30 21.84 720.89   
30.20 21.75 720.12 0.21  
30.50 22.05 722.99   
30.10 21.69 720.70   
30.00 21.66 722.10 0.11 0.18 
30.10 21.73 721.92   
30.10 21.67 719.90   
30.00 21.64 721.43 0.21  
30.10 21.76 722.94   
 
Mean of 
potency 
721.06 
  
a Mean of ten determinations. 
y = 12,440x + 10,421 
r = 0,9948 
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The precision of the assay was determined 
by repeatability and intermediate precision which 
results were expressed as the relative standard 
deviation (RSD) of a series of measurements in 
the same day and on different days respectively. 
In the microbiological assay, the number of 
replications per dose must be sufficient to ensure 
the required precision. Furthermore, the assay may 
be repeated and the results combined statistically 
to obtain the required precision [18]. The 
repeatability was studied by determination of the 
samples in three assays, at the same concentration, 
during the same day under the same experimental 
conditions. The result obtained shows RSD of 
0.11 indicating good intra-assay precision. Inter-
assay variability was calculated from assays on 4 
days and shows RSD of 0.18.  
The accuracy was proved by recovery test 
that are experimental designs to determine the 
agreement between the values found of the analyte 
and the real value that analyses [21-22]. The 
recovery test was performed with three different 
concentrations and the mean recovery was found 
to be 99.41 of reference substance (Table 4). 
 
 
Table 4. Experimental values obtained in the recovery test for 
cefpirome in powder for injection by microbiological cylinder – 
plate assay. 
Amount of 
standard 
added (mg) 
Amount of 
standard found 
(mg) 
Percentage recoverya ± 
RSD (%) 
0.300 0.304 101.37 ± 0.75 
0.600 0.597 99.46 ± 0.83 
1.200 1.192 99.31 ± 0.11 
a Mean of twenty determinations. 
 
The specificity of the proposed 
microbiological assay was studied analysis of 
degraded samples. The results obtained 
demonstrate that a decrease occurred in the 
potency of cefpirome under the conditions used. 
The results were expressed as a percentage of the 
drug remaining (Table 5). 
 
 
 
 
 
 
 
 
Table 5. Results of mean potency of cefpirome reconstituted in 
aqueous solution after storage at 5 °C for 24h, in 0.1 M potassium 
phosphate buffer, pH 8.0 at room temperature for 6h and after 
degradation by microbiological cylinder – plate assay. 
Sample 
Concentration 
(µg mL-1) 
Mean 
diameter zone 
of inhibition 
(mm), RSD 
(%)a 
Mean 
potency 
of sample 
(%) 
Standard 
0.30 
0.60 
1.20 
15.91 (1.13) 
19.93 (1.60) 
23.91 (1.15) 
100.00 
Sample 
0.30 
0.60 
1.20 
15.97 (1.40) 
20.09 (1.64) 
23.93 (1.67) 
101.40 
Standard solution 
stored at 5 °C, 
24h 
0.30 
0.60 
1.20 
16.00 (1.65) 
19.99 (1.32) 
23.87 (1.64) 
100.18 
Sample solution 
stored at room 
temperature, 6h 
0.30 
0.60 
1.20 
15.94 (1.95) 
20.08 (1.27) 
23.93 (1.58) 
100.44 
Degradated 
sample stored at 
40 °C for 4 days 
0.30 
0.60 
1.20 
----* 
----* 
----* 
----* 
Degradated 
sample (0.6 mg 
mL-1) stored at 
UV light (254 nm) 
4h  
0.30 
0.60 
1.20 
----* 
----* 
----* 
----* 
Degradated 
sample (6 mg mL-
1) stored at 40 °C 
for 4 h  
0.30 
0.60 
1.20 
----* 
----* 
----* 
----* 
a Mean of ten determinations’ 
* Total loss of potency 
 
To generate reproducible and reliable 
results, the stability of sample solution, standards 
and reagents must be determined prior to initiating 
the method validation studies. It is often essential 
that solutions be stable enough to allow for delays. 
Samples and standards should be tested over a 
time period and quantitation of components 
should be determined by comparison to freshly 
prepared standards. A stability criterion for assay 
methods is that sample and standard solutions be 
stable for under defined storage conditions. 
Acceptable stability is 2% change in standard or 
sample response, relative to freshly prepared 
standards [26]. 
The analytical solutions of cefpirome in 
water (reference - 200 µg mL
-1
), kept at 
refrigerated temperature (5 °C) for 24 hours, and 
0.1 M potassium phosphate buffer pH 8.0 (sample 
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– 0.3, 0.6 and 1.2 µg mL-1), kept at room 
temperature for 6 hours, exhibited no inhibition 
zone diameters changes (Table 5). 
Although the biological assays have a high 
variability, the results obtained in this assay were 
very satisfactory. Performed validation proved 
that microbiological assay is a good method for 
pharmaceutical analysis of cefpirome in raw 
material and powder for injection. 
 
 
Conclusion 
The results indicated that the 
microbiological cylinder-plate assay hold 
linearity, precision, accuracy and specificity at 
concentration ranging from 0.3 to 1.2 g mL-1 
being an acceptable method for the routine quality 
control of cefpirome in raw material and 
pharmaceutical preparation. 
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